[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE232902T1 - Anti-egfr einkettige fvs und anti-egfr antikoerper - Google Patents

Anti-egfr einkettige fvs und anti-egfr antikoerper

Info

Publication number
ATE232902T1
ATE232902T1 AT95913134T AT95913134T ATE232902T1 AT E232902 T1 ATE232902 T1 AT E232902T1 AT 95913134 T AT95913134 T AT 95913134T AT 95913134 T AT95913134 T AT 95913134T AT E232902 T1 ATE232902 T1 AT E232902T1
Authority
AT
Austria
Prior art keywords
pct
chain fvs
egfr
egfr antibodies
phage
Prior art date
Application number
AT95913134T
Other languages
English (en)
Inventor
A Cathrine Kettleborough
Mary M Bendig
Keith H Ansell
Detlef Guessow
Jaime Adan
Francesc Mitjans
Elisabet Rosell
Francesc Blasco
Jaime Piulats
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE232902T1 publication Critical patent/ATE232902T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95913134T 1994-03-17 1995-03-16 Anti-egfr einkettige fvs und anti-egfr antikoerper ATE232902T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94104160 1994-03-17
EP94118970 1994-12-02
PCT/EP1995/000978 WO1995025167A1 (en) 1994-03-17 1995-03-16 Anti-egfr single-chain fvs and anti-egfr antibodies

Publications (1)

Publication Number Publication Date
ATE232902T1 true ATE232902T1 (de) 2003-03-15

Family

ID=26135522

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95913134T ATE232902T1 (de) 1994-03-17 1995-03-16 Anti-egfr einkettige fvs und anti-egfr antikoerper

Country Status (20)

Country Link
US (1) US5844093A (de)
EP (1) EP0699237B1 (de)
JP (2) JPH08510922A (de)
KR (1) KR100376038B1 (de)
AT (1) ATE232902T1 (de)
AU (1) AU2071695A (de)
CA (1) CA2163012C (de)
CZ (1) CZ292061B6 (de)
DE (1) DE69529649T2 (de)
DK (1) DK0699237T3 (de)
ES (1) ES2191702T3 (de)
HU (1) HU221001B1 (de)
MX (1) MX9504802A (de)
NO (1) NO322252B1 (de)
PL (1) PL181342B1 (de)
PT (1) PT699237E (de)
RU (1) RU2170257C2 (de)
SK (1) SK283889B6 (de)
UA (1) UA41929C2 (de)
WO (1) WO1995025167A1 (de)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
WO1998012227A1 (en) * 1996-09-19 1998-03-26 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
CA2722378C (en) * 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
WO1999011792A1 (fr) * 1997-09-02 1999-03-11 Sumitomo Pharmaceuticals Company, Limited Anticorps a simple brin dirige contre une proteine noyau du virus de l'hepatite b, gene correspondant et agent therapeutique de l'hepatite b les contenant
DE19744531A1 (de) * 1997-10-09 1999-05-27 Klaus Dr Rer Nat Bosslet Bindemoleküle gegen Rezeptor-Ligand-Komplexe
CA2309679C (en) 1997-11-17 2010-07-20 Peter Kufer Method of identifying binding site domains that retain the capacity of binding to an epitope
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
CA2341276C (en) 1998-08-28 2005-10-11 Genentech, Inc. Human anti-factor ix/ixa antibodies
IL146480A0 (en) * 1999-05-14 2002-07-25 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US7361338B2 (en) * 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6790631B1 (en) * 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
AU2001258567A1 (en) * 2000-05-19 2001-11-26 Scancell Limited Humanised antibodies to the epidermal growth factor receptor
JPWO2001096401A1 (ja) * 2000-06-14 2004-06-10 株式会社医学生物学研究所 蛍光タンパク質を融合したｓｃＦｖ抗体の作製方法
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
DE60114830T2 (de) * 2000-06-28 2006-08-03 Glycofi, Inc. Verfahren zur herstellung modifizierter glycoproteine
US8697394B2 (en) 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
EP1311291A4 (de) * 2000-08-09 2007-07-25 Imclone Systems Inc Behandlung von hyperproliferativen krankheiten mit antagonisten des epidermalen wachstumsfaktors
EP1458411A4 (de) * 2000-08-21 2004-09-22 Smithkline Beecham Corp Anti-rank liganden monoklonale antikörper nützlich zur behandlung von rank liganden vermittelten störungen
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CA2433877C (en) * 2001-01-17 2014-11-18 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds
JP2004533815A (ja) 2001-03-14 2004-11-11 ミリアド・ジェネティックス・インコーポレイテッド Ｔｓｇ１０１−ｇａｇ相互作用およびその使用
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
ES2552281T3 (es) 2001-05-11 2015-11-26 Ludwig Institute For Cancer Research Ltd. Proteínas de unión específica y usos de las mismas
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CN100497389C (zh) * 2001-06-13 2009-06-10 根马布股份公司 表皮生长因子受体(egfr)的人单克隆抗体
ES2496493T3 (es) 2002-01-11 2014-09-19 Bioasis Technologies Inc. Uso de p97 como sistema de administración de enzimas para la administración de enzimas lisosómicas terapéuticas
WO2005117986A2 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody drug conjugates and methods
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
ATE535254T1 (de) 2002-07-15 2011-12-15 Genentech Inc Behandlung von krebs mit dem anti-erbb2- antikörper rhumab 2c4
JP5814494B2 (ja) 2002-11-12 2015-11-17 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
EP1622941A2 (de) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Methode zur produktion von anti-egfr antikörpern
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US7598350B2 (en) * 2004-03-19 2009-10-06 Imclone Llc Human anti-epidermal growth factor receptor antibody
EP2455400B1 (de) 2004-04-21 2019-03-20 The Brigham and Women's Hospital, Inc. Poly-N-acetylglucosamin (PNAG/DPNAG)-bindenden Peptide und Verwendungsverfahren dafür
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
UA97469C2 (uk) 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
EA013878B1 (ru) * 2005-12-06 2010-08-30 Домантис Лимитед Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
US7503217B2 (en) * 2006-01-27 2009-03-17 Weatherford/Lamb, Inc. Sonar sand detection
US8173374B2 (en) 2006-03-06 2012-05-08 Agency For Science, Technology And Research Human embryonic stem cell methods and PODXL expression
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
JP5382692B2 (ja) * 2006-07-10 2014-01-08 学校法人藤田学園 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
WO2008070780A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonist antibodies against ephb3
JP2010513321A (ja) * 2006-12-22 2010-04-30 ノヴェリクス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 少なくとも一種の上皮細胞増殖因子受容体特異抗体またはその誘導体を用いる糖尿病の治療
CA2676244C (en) 2007-01-25 2017-01-17 Kwok-Kin Wong Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
EP2134854B1 (de) 2007-03-15 2015-04-15 Ludwig Institute for Cancer Research Ltd. Behandlungsverfahren unter verwendung von egfr-antikörpern und src-inhibitoren und damit verbundene formulierungen
US20100322939A1 (en) * 2007-06-21 2010-12-23 Genmab A/S Novel methods for treating egfr-associated tumors
CN101896503B (zh) 2007-08-14 2018-05-22 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
BRPI0817108B8 (pt) 2007-09-21 2021-05-25 Univ California composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma.
CN105198997B (zh) 2008-04-11 2018-08-31 阿普拜佛研发有限责任公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
KR20110014607A (ko) 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CN102112494A (zh) 2008-06-03 2011-06-29 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
EP2297209A4 (de) 2008-06-03 2012-08-01 Abbott Lab Dual-variable- domain-immunglobuline und ihre verwendungen
WO2010006060A2 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
EP2315747B1 (de) 2008-07-21 2017-12-06 The Brigham and Women's Hospital, Inc. Verfahren und zusammensetzungen in verbindung mit synthetischen beta-1,6 glucosamin-oligosacchariden
KR101108642B1 (ko) * 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011063346A1 (en) * 2009-11-20 2011-05-26 Northshore University Health System Research Institute Targeting of the c-terminal segment of c. difficile toxin b for improved clinical diagnosis, prevention, and treatment
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
CN102167743B (zh) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗egfr单克隆抗体、其制备方法及用途
DK2560683T4 (da) 2010-04-23 2022-08-29 Hoffmann La Roche Fremstilling af heteromultimeriske proteiner
EP2578682B1 (de) * 2010-06-04 2016-07-27 Toagosei Co., Ltd. Antikörper und verwendung davon
UY33543A (es) 2010-08-03 2012-02-29 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
BR112013004581A2 (pt) 2010-08-26 2017-06-27 Abbvie Inc imunoglobulinas de domínio variável dual e seus usos
KR101273918B1 (ko) * 2010-09-17 2013-06-13 강원대학교산학협력단 인간 항-상피세포성 성장인자수용체 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물
CN105399831A (zh) 2010-10-29 2016-03-16 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
SG189929A1 (en) 2010-10-29 2013-06-28 Immunogen Inc Novel egfr-binding molecules and immunoconjugates thereof
JP6161540B2 (ja) 2011-02-04 2017-07-12 ジェネンテック， インコーポレイテッド Ｆｃ変異体及びそれらの生産方法
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CN110038135B (zh) 2011-03-17 2021-03-05 伯明翰大学 重新定向的免疫治疗
ES2582869T3 (es) 2011-07-05 2016-09-15 Bioasis Technologies Inc Conjugados de P97-anticuerpo
AU2012294673B2 (en) 2011-08-05 2015-11-26 Bioasis Technologies Inc. p97 fragments with transfer activity
ES2694153T3 (es) 2011-09-30 2018-12-18 Regeneron Pharmaceuticals, Inc. Anticuerpos anti-ErbB3 y usos de los mismos
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
WO2013059885A2 (en) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
CN104066481A (zh) 2011-11-21 2014-09-24 伊缪诺金公司 利用egfr抗体细胞毒性剂缀合物治疗抗egfr疗法的肿瘤的方法
AU2012362326A1 (en) 2011-12-30 2014-07-24 Abbvie Inc. Dual variable domain immunoglobulins against IL-13 and/or IL-17
CN104203286B (zh) * 2012-03-21 2017-12-29 弗劳恩霍夫应用研究促进协会 用于光动力疗法的新型光免疫偶联物
JP6441792B2 (ja) * 2012-05-17 2018-12-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｇｆｒに結合する抗原結合蛋白質
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
JP6433424B2 (ja) 2012-07-31 2018-12-05 バイオアシス テクノロジーズ インコーポレイテッド 脱リン酸化されたリソソーム蓄積症タンパク質およびその使用方法
AR093311A1 (es) 2012-11-01 2015-05-27 Abbvie Inc Inmunoglobulinas de dominio variable dual contra el factor de crecimiento endotelial vascular (vegf) y el ligando involucrado en la señalizacion celula a celula a traves del receptor notch (dll4)
EP2970433B1 (de) 2013-03-13 2019-09-18 Bioasis Technologies Inc. Fragmente von p97 und verwendungen davon
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
EP2992013B1 (de) 2013-04-29 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38-antikörper und fusionen davon mit abgeschwächtem interferon-alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
EP3038657A2 (de) 2013-08-28 2016-07-06 Bioasis Technologies Inc. Cns-gerichtete konjugate mit modifizierten fc-regionen und verfahren zur verwendung davon
US20160347821A1 (en) 2014-02-03 2016-12-01 Bioasis Technologies, Inc. P97 fusion proteins
AU2015219339B2 (en) 2014-02-19 2020-03-05 Bioasis Technologies Inc. P97-IDS fusion proteins
WO2015168521A2 (en) 2014-05-01 2015-11-05 Bioasis Technologies, Inc. P97-polynucleotide conjugates
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
CN106471117A (zh) 2014-05-06 2017-03-01 豪夫迈·罗氏有限公司 使用哺乳动物细胞产生异多聚体蛋白
CA2952026A1 (en) 2014-06-13 2015-12-17 Tenboron Oy Conjugates comprising an anti-egfr1 antibody
WO2016065409A1 (en) 2014-10-29 2016-05-06 Teva Pharmaceuticals Australia Pty Ltd INTERFERON α2B VARIANTS
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
CN110087673A (zh) 2016-07-19 2019-08-02 梯瓦制药澳大利亚股份有限公司 抗cd47联合治疗
WO2018152033A1 (en) * 2017-02-14 2018-08-23 Promab Biotechnologies, Inc. Cd47-car-t cells
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3621994A4 (de) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. Mesothelinbindende proteine
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
CA3078799A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
CN109879964B (zh) * 2017-12-06 2022-08-05 北京科立思维生物科技有限公司 抗egfr单链抗体、抗pd1单链抗体及融合蛋白
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
MX2021003554A (es) 2018-09-25 2021-05-27 Harpoon Therapeutics Inc Proteinas de union a dll3 y metodos de uso.
CA3120800A1 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
WO2021222944A1 (en) * 2020-04-30 2021-11-04 Board Of Regents, The University Of Texas System Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof
EP3954393A1 (de) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Kombinationstherapien zur verabreichung über die blut-hirn-schranke hinweg
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
EP4376958A1 (de) 2021-07-30 2024-06-05 Affimed GmbH Duplexkörper
AU2022382368A1 (en) 2021-11-03 2024-05-02 Affimed Gmbh Bispecific cd16a binders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016842A1 (en) * 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US5395750A (en) * 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
GB9401182D0 (en) * 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect

Also Published As

Publication number Publication date
HU221001B1 (hu) 2002-07-29
KR100376038B1 (ko) 2003-06-09
SK143095A3 (en) 1996-11-06
WO1995025167A1 (en) 1995-09-21
HUT73461A (en) 1996-08-28
EP0699237B1 (de) 2003-02-19
NO954626D0 (no) 1995-11-16
JP2006025794A (ja) 2006-02-02
ES2191702T3 (es) 2003-09-16
NO954626L (no) 1995-11-16
HU9503285D0 (en) 1996-02-28
NO322252B1 (no) 2006-09-04
DE69529649T2 (de) 2003-12-18
PL181342B1 (pl) 2001-07-31
DE69529649D1 (de) 2003-03-27
AU2071695A (en) 1995-10-03
DK0699237T3 (da) 2003-05-26
CZ301495A3 (en) 1996-02-14
CA2163012A1 (en) 1995-09-21
EP0699237A1 (de) 1996-03-06
US5844093A (en) 1998-12-01
PL311661A1 (en) 1996-03-04
PT699237E (pt) 2003-07-31
RU2170257C2 (ru) 2001-07-10
SK283889B6 (sk) 2004-04-06
JPH08510922A (ja) 1996-11-19
CA2163012C (en) 2009-12-08
CZ292061B6 (cs) 2003-07-16
MX9504802A (es) 1997-05-31
UA41929C2 (uk) 2001-10-15

Similar Documents

Publication Publication Date Title
ATE232902T1 (de) Anti-egfr einkettige fvs und anti-egfr antikoerper
GEP20074222B (en) Antibodies to cd40
HUP0101160A2 (hu) Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására
EA012079B3 (ru) Моноклональное антитело к рецептору инсулиноподобного фактора роста i (igf-i) и способы его применения
AU2003220525A1 (en) Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
ATE191487T1 (de) Antikörper gegen das carcinoembryonic antigen
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
AR047372A1 (es) Anticuerpos contra madcam
NO942912L (no) Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5
MY137078A (en) Recombinant antibodies associated to gangliosides. their use indiagnosis and treatment of tumors.
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
ES2173910T3 (es) Anticuerpos humanizados dirigidos contra el antigeno a33.
WO2022034524A3 (en) Antibodies against ilt2 and use thereof
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
WO2022015716A3 (en) Novel anti-pd1 antibodies for inhibiting t-cell activity
WO2024191972A3 (en) Anti-lipocalin-2 antibodies and uses thereof
UA84539C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с cd40, фармацевтическая композиция, которая его содержит, и применение антитела для производства лекарственного средства для лечения cd 40-отрицательной опухоли у человека
NO20055312L (no) Farmasoytisk sammensetning omfattende et biospesifikt antistoff for EPCAM

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0699237

Country of ref document: EP

REN Ceased due to non-payment of the annual fee